Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04250311
Recruitment Status : Recruiting
First Posted : January 31, 2020
Last Update Posted : February 10, 2020
Sponsor:
Information provided by (Responsible Party):
Materia Medica Holding

Brief Summary:

The main purpose of this study is:

• to evaluate the efficacy and safety of MMH-407 in the treatment of influenza in outpatient adults.


Condition or disease Intervention/treatment Phase
Influenza Drug: MMH-407 Drug: Placebo Phase 3

Detailed Description:

Design: a multicenter, placebo-controlled, double-blind, randomized clinical trial in parallel groups.

The study will include both male and female patients aged 18-64 years with clinical signs of influenza within the first 24 hours of the onset of illness.

The influenza diagnosis must be supported by a positive rapid test (detection of influenza virus antigens in nasal epithelial cells). After the patients provide signed Participant Information Sheet and Informed Consent form, their medical history and body temperature will be recorded and physical examination and rapid diagnostic test performed. Patients who test positive will be assessed for 7 influenza-associated symptoms: cough, sore throat, headache, nasal congestion, feverishness or chills, muscle or joint pain, fatigue.

4-point Flu Symptom Severity scale will be used: 0 = no symptom; 1 = mild symptom; 2 = moderate symptom; 3 = severe symptom.

Nasopharyngeal swabs will be obtained from these patients for subsequent real-time reverse transcription polymerase chain reaction (RT-PCR) influenza A/B testing and laboratory tests performed.

If a patient meets all inclusion criteria and does not meet any of the exclusion criteria at Visit 1 (Day 1), he/she will be randomized into one of the treatment groups: Group 1: ММН-407 for 5 days, or Group 2: Placebo on the ММН-407 regimen for 5 days.

The patients will use electronic patient diaries to daily record their morning and evening axillary temperature (taken using a Geratherm mercury-free thermometer) and severity of 7 influenza-associated symptoms (using the Flu Symptom Severity scale). In addition to this, the patients will record doses of antipyretic drugs taken (when applicable) and any worsening of their health status (when applicable, to assess treatment safety and collect adverse events data).

In total, patients will be observed for 14 days (screening and randomization - up to 24 hours, treatment - 5 days, subsequent observation - up to 2 days; and a follow-up 'telephone' visit - Day 14).

During the study, 3 visits from patient to the physician's office and a follow-up telephone visit will be accomplished: 1) patient visits - Days 1, 3 and 7 (Visits 1, 2, and 3) at the medical centre; 2) telephone visit from the physician (Visit 4) - Day 14.

During Visits 2 and 3, the physician will perform a physical examination, record the changes in patients' symptoms and the use of concomitant medications and check the completion of patient diaries. At Visit 2, nasopharyngeal swabs for RT-PCR will be collected. Visit 3 will involve an assessment of treatment compliance and laboratory tests. The telephone visit is intended to provide information on a patient's health status, presence/absence of secondary bacterial complications and the use of antibiotics.

During the study, subjects will be allowed to use symptomatic therapy and medications for their co-morbidities, except for the medicines listed in the "Prohibited Concomitant Medications" section.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 314 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Placebo-controlled, Double-blind, Randomized Clinical Trial in Parallel Groups to Evaluate the Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults
Actual Study Start Date : December 12, 2019
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : December 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot

Arm Intervention/treatment
Experimental: MMH-407
Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.
Drug: MMH-407
MMH-407: For oral use.

Placebo Comparator: Placebo
Oral administration. Single dose: 1 tablet. First 24 hours of therapy: 1 tablet every 30 minutes for the first 2 hours, followed by 3 more tablets taken at regular intervals during the rest of the day. Days 2 to 5: 1 tablet 3 times daily.
Drug: Placebo
Placebo: For oral use.




Primary Outcome Measures :
  1. Time to improvement of influenza symptoms. [ Time Frame: On days 1-14 of observation. ]
    Based on patient diaries. In the morning and in the evening, the patients rate the severity of their symptoms on a 4-point scale (7 symptoms of influenza): headache, fever/chill, aches in the muscles/joints, weakness/drowsiness, cough, sore throat, and nasal congestion, where the absence of symptoms is 0, mild symptoms - 1, moderate symptoms - 2, and severe symptoms is 4. "Improvement of influenza symptoms" means no or mild symptoms.


Secondary Outcome Measures :
  1. Proportion of patients reporting improvement of influenza symptoms. [ Time Frame: On days 1-14 of observation period. ]
    Based on patient diaries.

  2. Severity of illness. [ Time Frame: On days 1- 6 of the observation period. ]
    Total symptom score AUC (to be estimated from each of the seven symptom subscores).

  3. Proportion of patients with negative virus shedding. [ Time Frame: On day 3 of the observation period. ]
    Negative influenza RT-PCR on nasopharyngeal swabs.

  4. Dosing frequency of antipyretics according to indications. [ Time Frame: On days 1-3 of the treatment period. ]
    A decrease dosing frequency of antipyretics while taking MMN-407 is one of the criteria for effectiveness.Based on patient diaries.

  5. Proportion of subjects reporting worsening of illness. [ Time Frame: On days 4 -14 of the observation period. ]
    Worsening of illness is bacterial complication of influenza that require the use of antibiotics or hospitalization.

  6. Occurrence and nature of adverse events (AE). [ Time Frame: On days 1-5 of the treatment period. ]
    AE severity, causal relationship to the study drug and outcome.

  7. Number of patients with treatment-related changes in vital signs: body temperature, pulse rate (heart rate), respiration rate (breathing rate), and blood pressure. [ Time Frame: On days 1- 5 of the treatment period. ]
    Based on medical records. Vital signs will be measured in a medical setting.

  8. Proportion of subjects with clinically significant abnormal laboratory data. [ Time Frame: On days 1- 5 of the treatment period. ]
    Вased on medical records.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients of male and female gender aged 18 to 64 years.
  2. Uncomplicated, moderate influenza supported by all the symptoms:

    • axillary temperature ≥38.1°С on physician examination;
    • at least one moderate general symptom of influenza infection (headache, fever/chill, aches in the muscles/joints, weakness/drowsiness);
    • at least one moderate respiratory symptom of influenza infection (cough, sore throat, or nasal congestion).
  3. Positive influenza rapid test (detection of virus antigens in the nasal epithelium).
  4. First 24 hours of the onset of illness.
  5. Patients who agree to use a reliable method of birth control during the study.
  6. Patients who have provided signed Participant Information Sheet and Informed Consent form to participate in a clinical trial.

Exclusion Criteria:

  1. Severe influenza infection that requires hospitalization.
  2. Suspected pneumonia or bacterial infection (including otitis media, sinusitis, urinary tract infection, meningitis, sepsis, etc.) that requires the use of antibiotics, starting from the first day of illness.
  3. Suspected early manifestations of a condition that, on its first onset, produces symptoms similar to those of influenza (other infectious diseases and/or influenza-like syndrome associated with the first onset of a systemic connective tissue disorder or another condition).
  4. Patients who require the use of antivirals that are not permitted during the study.
  5. Current season influenza vaccination.
  6. Prior history or diagnosis of primary or secondary immunodeficiency
  7. Patients with any known or suspected malignant neoplasm.
  8. An exacerbated or decompensated chronic disease interfering with the subject's participation in the clinical trial.
  9. Malabsorption syndrome, including congenital or acquired lactase deficiency (or any other disaccharidase deficiency), and/or galactosemia.
  10. Current allergy to or intolerance of the active substances or any of the excipients in the medications used in the treatment.
  11. Pregnancy, breast-feeding, childbirth within less than 3 months prior to the inclusion in the trial, or unwillingness to use contraceptive methods during the study
  12. Prior history of non-adherence to medication; mental disorder; or alcohol or substance abuse, which, in the investigator's opinion, will compromise compliance with study procedures.
  13. Use of any of the "Prohibited Concomitant Medications" within 2 weeks prior to study entry.
  14. Patients who, as judged by the investigator, will fail or be unwilling to comply with the observation requirements or adhere to the dosing regimen during the study.
  15. Participation in other clinical studies within 3 months prior to the inclusion in this study.
  16. Patients who are related to any of the on-site research personnel directly involved in the conduct of the study or are an immediate relative of the investigator. 'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted).
  17. Patients who work for OOO "NPF "Materia Medica Holding" (i.e. company employees, temporary contract workers, designated officials responsible for carrying out the research or any immediate relatives of the aforementioned).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04250311


Contacts
Layout table for location contacts
Contact: Mikhail Putilovskiy, MD, PhD +74952761571 ext 302 PutilovskiyMA@materiamedica.ru

Locations
Show Show 32 study locations
Sponsors and Collaborators
Materia Medica Holding
Layout table for additonal information
Responsible Party: Materia Medica Holding
ClinicalTrials.gov Identifier: NCT04250311    
Other Study ID Numbers: MMH-407-002
First Posted: January 31, 2020    Key Record Dates
Last Update Posted: February 10, 2020
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases